Quoin Pharmaceuticals (QNRX) Common Equity (2018 - 2026)
Quoin Pharmaceuticals (QNRX) posted Common Equity of $8.8 million for Q1 2026, down 33.13% sequentially from $13.1 million in Q4 2025, and up 48.05% YoY from $5.9 million in Q1 2025.
Quoin Pharmaceuticals (QNRX) Common Equity (2018 - 2026) Analysis & Trends
Quoin Pharmaceuticals has reported Common Equity for 9 years, with the latest figure at $8.8 million in Q1 2026.
- Quarterly Common Equity rose 48.05% year-over-year to $8.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.8 million (up 48.05% YoY) and the FY2025 annual result came in at $13.1 million, up 42.54% from the prior year.
- Common Equity eased to $8.8 million in Q1 2026 per QNRX's latest filing, from $13.1 million in the prior quarter.
- Over five years, Common Equity peaked at $13.1 million in Q4 2025 and troughed at -$3.2 million in Q2 2022.
- A 5-year average of $6.2 million and a median of $7.4 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2025: Common Equity surged 1596.34% in 2023, then sank 122.32% in 2025.
- Over 5 years, Common Equity stood at $7.4 million in 2022, then dropped by 23.53% to $5.7 million in 2023, then soared by 62.51% to $9.2 million in 2024, then surged by 42.54% to $13.1 million in 2025, then slumped by 33.13% to $8.8 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $8.8 million, $13.1 million, and -$1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Quoin Pharmaceuticals | 491,038.58 | 491,038.58 | - | 3.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.77 Mn |
| Dec 31, 2025 | 13.12 Mn |
| Sep 30, 2025 | -1.21 Mn |
| Jun 30, 2025 | 2.55 Mn |
| Mar 31, 2025 | 5.93 Mn |
| Dec 31, 2024 | 9.20 Mn |
| Sep 30, 2024 | 5.44 Mn |
| Jun 30, 2024 | 7.48 Mn |
| Mar 31, 2024 | 9.13 Mn |
| Dec 31, 2023 | 5.66 Mn |
| Sep 30, 2023 | 7.41 Mn |
| Jun 30, 2023 | 9.07 Mn |
| Mar 31, 2023 | 10.91 Mn |
| Dec 31, 2022 | 7.41 Mn |
| Sep 30, 2022 | 9.17 Mn |
| Jun 30, 2022 | -3.17 Mn |
| Mar 31, 2022 | -729,408.00 |
| Dec 31, 2021 | 657,032.00 |
| Sep 30, 2021 | -16.25 Mn |
| Jun 30, 2021 | -14.85 Mn |